

The Chinese Pharmaceuticals market journey to 2024

14 April 2014 | Reports/white papers | By BioSpectrum Bureau

The Chinese Pharmaceuticals market journey to 2024



In Bharat Book Bureau report China's pharmaceutical sales growth is based on economic growth in the country. This has resulted in increased healthcare expenditure internally, and increased manufacture and export. This report gives us a keen insights into the Chinese Pharmaceutical industry by the year 2024. Increasing urbanization, disposable income, aging population, health education, lifestyle diseases and government investments and initiatives for healthcare infrastructure improvement have helped the market growth considerably.

From 2008 to 2013, China's OTC drugs market reported an average growth of 15% with the market reaching \$20.6bn in 2013 up from to \$11bn in 2008 - but what will it be this year? Next year? and in 5 years time?

The OTC drugs market in China was characterized by a late start, but fast growth, along with huge potential in comparison to that of the mature OTC markets in many western countries. Your company should be benefiting from this market access - and this is only the OTC market - what has the growth been throughout the whole Chinese pharma sector? This report will tell you.

Annually, an average of \$190 is spent for the treatment of diabetes, per patient, in China. By 2030, in China, diabetes is expected to cost Yuan 173.4bn (\$28 bn) a year. China is expected to top the world's diabetes tables both in terms of sheer numbers and population prevalence.

Counterfeit drugs are successfully introduced in to the lengthy and complicated delivery chain because of the highly fragmented nature of the market. A lack of regular inspections by any recognized drug enforcement / regulatory bodies, again due to the highly fragmented nature of production, allows counterfeit / poor quality drugs into the Chinese pharma market. Moreover, wide spread corruption also helps the distribution of counterfeit drugs. What are the Chinese regulators, and the global manufacturers doing to change this? Find out in this unique report.

Increased inward investment from multiple 'Big Pharma' companies has driven investment in R&D centres as well as opportunities for Chinese graduates. Many graduates are staying in China; those that have left now have jobs to return to. Are you producing enough of your products in China? Increase your profitability through this channel.

Domestically, increased levels of health insurance, increased health education, rising numbers of hospitals and increased per capita income have all driven the Chinese pharmaceutical market.